Maintenance therapy (MT) with oral methotrexate (MTX) and 6-mercaptopurine (6-MP) is
essential for the cure of acute lymphoblastic leukemia (ALL). MTX and 6-MP interfere with …

The discovery and identification of biomarkers promote the rational and fast development of
medical diagnosis and therapeutics. Clinically, the application of ideal biomarkers still is …

Background Cytidine deamination that is guided by clustered regularly interspaced short
palindromic repeats (CRISPR) can mediate a highly precise conversion of one nucleotide …

Derivation of CD7-targeted chimeric antigen receptor (7CAR) T cells often requires genetic
manipulations to ablate the CD7 gene or block CD7 cell surface expression. Our novel …

PURPOSE To improve the outcomes of patients with T-cell acute lymphoblastic leukemia (T-
ALL) and lymphoblastic lymphoma (T-LL), the proteasome inhibitor bortezomib was …

Childhood acute lymphoblastic leukemia is a genetically heterogeneous cancer that
accounts for 10–15% of T-cell acute lymphoblastic leukemia (T-ALL) cases. The T-ALL event …

Nelarabine, an antimetabolite prodrug, is approved as monotherapy for children and adults
with relapsed and refractory T-cell acute lymphoblastic leukemia and lymphoma (R/R T …

Background: N6-methyladenosine (m6A), 5-methylcytosine (m5C) and N1-methyladenosine
(m1A) are the main RNA methylation modifications involved in the progression of cancer …

T-cell lymphoblastic lymphoma (T-LLy) and T-cell acute lymphoblastic leukemia (T-ALL)
have historically been considered a spectrum of the same disease. However, recent …

Non-B-cell acute leukemia is a term that encompasses T-cell acute lymphoblastic leukemia
(T-ALL) and acute myeloid leukemia (AML). Currently, the therapeutic effectiveness of …